Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Issue 4 (April 2015)

• Record Type: Journal Article
• Authors: Jacobsen, Eric; Pozdnyakova, Olga; Redd, Robert; Fisher, David C.; Dorfman, David M.; Dal Cin, Paola; LaCasce, Ann; Armand, Philippe; Hochberg, Ephraim; Cote, Gregory; Shahsafaei, Ali; Neuberg, Donna; Brown, Jennifer R.; Freedman, Arnold S.
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 4(2015:Apr.)
• Page Start: 993
• Page End: 998
• Publication Date: 2015-04
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.941835
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Platelet derived growth factor-α (PDGFR-α) is expressed in peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Imatinib mesylate demonstrated <italic>in vitro</italic> cytotoxicity against primary PTCL, NOS cells. We initiated a trial of imatinib in 12 patients with relapsed or refractory T-cell non-Hodgkin lymphoma (T-NHL). PDGFR-α expression by immunohistochemistry and fluorescence <italic>in situ</italic> hybridization (FISH) to assess for FIP1L1–PDGFR-α fusion and/or PDGFR-α amplification were not required for study entry. We documented no objective responses. The median progression-free survival was 21.0 days (90% confidence interval [CI] 15.0, 28.0) and median overall survival was 154 days (90% CI 35, 242). Four patients had tissue available for analysis of PDGFR-α by immunohistochemistry and three of these patients' tumors expressed PDGFR-α. Imatinib was not effective for the treatment of peripheral T cell lymphoma in an unselected group of patients in which PDGFR-α expression was not required for study entry.</p> </abstract>